<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132654">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01687478</url>
  </required_header>
  <id_info>
    <org_study_id>13702</org_study_id>
    <secondary_id>F1D-CR-HGNB</secondary_id>
    <nct_id>NCT01687478</nct_id>
  </id_info>
  <brief_title>A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression</brief_title>
  <official_title>A Study to Assess the Short-Term Efficacy and Safety of Olanzapine and Fluoxetine Compared to Placebo and Fluoxetine for Nonpsychotic Treatment-Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine
      compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in
      Chinese participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Change from Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline, up to 8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale</measure>
    <time_frame>Baseline, up to 8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS)</measure>
    <time_frame>Baseline, up to 8 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36)</measure>
    <time_frame>Baseline, up to 8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline to 8 Week Endpoint in the Sheehan Disability Scale (SDS)</measure>
    <time_frame>Baseline, up to 8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve a Response Based on a ≥50% Reduction from Baseline in MADRS Total Score</measure>
    <time_frame>Baseline up to 8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Remission Based on MADRS Total Score ≤10 at 8 Weeks</measure>
    <time_frame>Baseline up to 8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline to 8 Week Endpoint in the Barnes Akathisia Scale (BAS)</measure>
    <time_frame>Baseline, up to 8 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline to 8 Week Endpoint in the Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>Baseline, up to 8 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">229</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Olanzapine + Fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine starting dose is 5 milligram (mg) (1 tablet). May titrate up to 10 mg (2 tablets), or 15 mg (3 tablets) administered once daily by mouth for 8 weeks.
Fluoxetine starting dose is 20 mg. May titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Fluoxetine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matches the Olanzapine tablet for blinding.
Fluoxetine starting dose is 20 mg, then may titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Administered Orally</description>
    <arm_group_label>Olanzapine + Fluoxetine</arm_group_label>
    <other_name>LY170053</other_name>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Administered Orally</description>
    <arm_group_label>Olanzapine + Fluoxetine</arm_group_label>
    <arm_group_label>Placebo + Fluoxetine</arm_group_label>
    <other_name>LY110140</other_name>
    <other_name>Prozac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered Orally</description>
    <arm_group_label>Placebo + Fluoxetine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have single or recurrent unipolar major depressive disorder (MDD) without psychotic
             features by Diagnostic and Statistical Manual of Mental Disorders, Fourth
             Edition-Text Revision (DSM-IV-TR) clinical assessment

          -  Have a total score ≥22 on the 17-item Hamilton Depression Rating Scale (HAM-D17) at
             screening and randomization

          -  Have treatment-resistant depression (TRD), defined as having failed to achieve a
             satisfactory antidepressant response, in the opinion of the investigator, to separate
             treatment courses of at least 2 different antidepressants, other than fluoxetine, of
             adequate dosage and duration (≥6 weeks) within the current major depressive episode

        Exclusion Criteria:

          -  Have a diagnosis of Parkinson's disease or a related disorder

          -  Have a current or lifetime diagnosis of any of the following conditions, according to
             DSM-IV-TR criteria: Schizophrenia; Schizophreniform Disorder; Schizoaffective
             Disorder; Delusional Disorder; Psychotic Disorder Not Otherwise Specified; Bipolar
             Disorder I or II; Delirium of any type; Dementia of any type; Amnestic Disorder; any
             Substance-Induced Disorder; or any Psychotic Disorder due to a General Medical
             Condition

          -  Have a current diagnosis of post-partum depression or MDD with a seasonal pattern as
             defined in the DSM-IV-TR

          -  Have paranoid, schizoid, schizotypal, antisocial, or borderline personality disorder
             (Axis II) as a comorbid or primary diagnosis, based on DSM-IV-TR criteria

          -  Have DSM-IV-TR substance dependence/abuse or are not willing to avoid use of the
             substance (not including dependence on nicotine or caffeine) within 30 days of
             screening

          -  Are actively suicidal in the judgment of the investigator

          -  Have uncorrected narrow-angle glaucoma

          -  Have had one or more seizures without a clear and resolved etiology

          -  Have leukopenia

          -  Have any acute, serious, or unstable medical conditions

          -  Have an increased serum prolactin concentration at screening

          -  Have a rate-corrected cardiac QT interval, calculated using Bazett's formula (QTc
             Bazett's [QTcB]), on Electrocardiogram (ECG) &gt;450 milliseconds (male) or &gt;470
             milliseconds (female) at screening

          -  Have a history of allergic reaction to olanzapine, fluoxetine, or olanzapine in
             combination with fluoxetine

          -  Have had treatment with olanzapine, fluoxetine, or olanzapine in combination with
             fluoxetine withdrawn due to clinically significant and/or intolerable adverse effects
             within 6 months of screening

          -  Have received treatment with remoxipride within 6 months of randomization

          -  Have received treatment with depot antipsychotics within one dosing interval before
             randomization

          -  Have received electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS)
             treatment within the current MDD episode, or has a history of failure to respond to
             adequate treatment courses of ECT or VNS, or is expected to require ECT or VNS at any
             time during the study

          -  Have received previous treatment with clozapine

          -  Have received treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of
             screening, or are expected to need MAOI treatment at any time during the study or up
             until 5 weeks after study discontinuation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There maybe multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559)</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baoding</city>
        <zip>071000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changsha</city>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guang Zhou</city>
        <zip>560370</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hangzhou</city>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kunming</city>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nanjing</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wu Han</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Xi'An</city>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Xinxiang</city>
        <zip>453002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 17, 2013</lastchanged_date>
  <firstreceived_date>September 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
